For this experiment, we used Melphalan, a clinically used cytostatic for multiple myeloma treatment [52], and we observed that Melphalan increases the number of XRCC1-positive DNA repair foci, but no changes were found when we compared m8A RNA nuclear level and γH2AX-positive foci in non-treated and Melphalan-treated cells (Fig. 4G). This evidence concerns the gene XRCC1 and plasma cell myeloma.